Shorter Versus Standard Antithyroid Drug Therapy in Graves’ Disease with Lower Baseline Thyrotropin Receptor Antibody (TRAb) Levels: Relapse Outcomes from a Propensity-Weighted Analysis
Authors' conclusion
Among patients with Graves' disease and lower TRAb levels, shorter ATD courses (<12 months) produced outcomes broadly comparable to 12-18 months.
Study context
- Population
- Adults with GD and baseline TRAb >1.8 and <10.0 U/L treated with antithyroid drug (ATDs), single centre
- Participants
- 369 adults104 propensity-score matching (PSM) pairs
- Exposure
- ATD duration <12 months vs 12-18 months
- <12 monthsn = 134
- 12-18 monthsn = 235reference
- Outcome
- Relapse within 12 months of ATD cessation
- Follow-up
- 12 months
Methodological detailssingle-centre, real-world data, prespecified risk-difference non-inferiority framework, inverse-probability-of-treatment weighting, 1:1 propensity-score matching
- Single-centre
- Real-world data
- Prespecified risk-difference non-inferiority framework
- Inverse-probability-of-treatment weighting
- 1:1 propensity-score matching
Main finding
As reported in the abstract
- Inverse-probability-of-treatment weighting (IPTW)-adjusted risk difference
- −1.5% (CI −11.0 to +8.0) (CI)
- Unadjusted risk difference
- −3.2%
- PSM risk difference
- +2.9%, CI −7.3 to +13.1 (CI)
Observational data: associations, not effects.
Secondary outcomes
Long-term relapse · median follow-up 58 months
- Long-term outcomes similar between groups; IPTW Cox HR
- 0.92 [CI 0.65-1.31] (CI)
- Restricted mean survival time (RMST) difference over 60 months
- +3.2 months [−2.1 to +8.4] (CI)
TRAb levels at cessation · ATD cessation
- TRAb levels at cessation were comparable
Original publication
Shorter Versus Standard Antithyroid Drug Therapy in Graves’ Disease with Lower Baseline Thyrotropin Receptor Antibody (TRAb) Levels: Relapse Outcomes from a Propensity-Weighted Analysis. Thyroid. Published 21 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →